We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 416.99 -0.2798% AAPL 236.12 0.4766% NVDA 141.89 2.8188% GOOGL 163.9 0.2937% GOOG 165.62 0.3453% AMZN 188.49 -0.2646% META 572.8 -0.6366% AVGO 179.26 -0.3502% TSLA 217.715 -1.3525% TSM 201.3996 0.3086% LLY 907.515 -1.1389% V 287.48 -1.0804% JPM 223.49 -0.8342% UNH 572.61 0.5267% NVO 117.1969 -0.7563% WMT 81.0075 -0.372% LVMUY 132.13 -2.3429% XOM 120.405 0.3291% LVMHF 664.5 -1.9483% MA 515.685 -0.1269%

Talis Biomedical Corp

Healthcare US TLIS

1.7USD
-2.68(61.19%)

Last update at 2024-10-21T18:37:00Z

52 Week Range

4.359.60
LowHigh

Fundamentals

  • Previous Close 4.38
  • Market Cap16.40M
  • Volume5539
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-58.31100M
  • Revenue TTM0.99M
  • Revenue Per Share TTM0.54
  • Gross Profit TTM -149.39800M
  • Diluted EPS TTM-31.43

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -113.01200M -192.03600M -91.13000M -27.47400M -21.33700M
Minority interest - - - - -
Net income -110.88500M -190.45800M -91.07600M -27.43200M -21.33700M
Selling general administrative 40.73M 42.42M 13.10M 6.86M 5.43M
Selling and marketing expenses - - - - -
Gross profit -4.73900M - 10.94M - 2.39M
Reconciled depreciation 8.83M 1.58M 0.76M 0.73M 0.65M
Ebit -123.96900M -193.39400M -91.18400M -26.69900M -21.43000M
Ebitda -115.13900M -191.81600M -90.42100M -25.97300M -20.78300M
Depreciation and amortization 8.83M 1.58M 0.76M 0.73M 0.65M
Non operating income net other - - - - -
Operating income -115.13900M -191.81600M -91.18400M -26.69900M -21.43000M
Other operating expenses 118.79M 191.82M 91.18M 26.70M 21.43M
Interest expense -2.12700M 1.36M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - 0.05M 0.04M 0.09M
Net interest income - - 0.05M 0.04M 0.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.12700M -1.57800M -0.05400M -0.04200M 0.09M
Total revenue 3.65M 0.00001M 10.94M 3.98M 2.39M
Total operating expenses 110.40M 191.82M 91.18M 26.70M 21.43M
Cost of revenue 8.39M - - - -
Total other income expense net 2.13M -0.22000M 0.05M -0.77500M 0.09M
Discontinued operations - - - - -
Net income from continuing ops -113.01200M -192.03600M -91.13000M -27.47400M -21.33700M
Net income applicable to common shares -113.01200M -192.03600M -91.13000M 26.38M -21.33700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 98.34M 169.29M 265.83M 198.41M 25.73M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.90M 2.78M 3.39M 3.11M 0.70M
Total liab 29.22M 42.55M 31.85M 306.98M 46.87M
Total stockholder equity 69.12M 126.74M 233.98M -108.57100M -21.14000M
Deferred long term liab - - - - -
Other current liab 4.55M 5.20M 1.08M 0.72M 2.47M
Common stock - 0.00300M 0.00300M - -
Capital stock 0.00300M 0.00600M 0.00600M 0.00000M 0.00000M
Retained earnings -539.96100M -477.95400M -364.94200M -172.90600M -81.77600M
Other liab - - - - 0.08M
Good will - - - - -
Other assets 0.00000M 1.78M 29.71M 0.57M 0.09M
Cash 76.73M 130.19M 232.54M 138.48M 21.60M
Cash and equivalents - - - - -
Total current liabilities 8.77M 12.67M 19.11M 16.03M 4.04M
Current deferred revenue - - 11.67M 9.71M -
Net debt -57.06400M -96.60900M -218.56800M -137.79000M -21.60400M
Short term debt 2.88M 3.70M 1.23M 0.69M -
Short long term debt - - - - -
Short long term debt total 19.67M 33.58M 13.98M 0.69M -
Other stockholder equity 609.07M 604.69M 598.91M -226.61000M 60.64M
Property plant equipment - 34.23M 23.43M 9.68M 1.53M
Total current assets 77.68M 133.28M 236.12M 188.72M 24.11M
Long term investments - - - - -
Net tangible assets - 126.74M 233.97M -108.57100M -21.14000M
Short term investments - - - - -
Net receivables 0.05M 0.31M 0.18M 0.47M 1.81M
Long term debt - - - - -
Inventory - - - 46.66M -
Accounts payable 1.34M 3.77M 5.12M 4.91M 1.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -2.23500M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.54M 1.78M 6.28M - 0.09M
Deferred long term asset charges - - - - -
Non current assets total 20.66M 36.01M 29.71M 9.68M 1.63M
Capital lease obligations 19.67M 33.58M 13.98M 0.69M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.61500M -2.86600M -8.20100M -0.57800M -0.53300M
Change to liabilities -1.19400M 0.22M 3.20M 0.18M 0.60M
Total cashflows from investing activities -1.61500M -2.86600M -8.20100M -0.57800M -0.53300M
Net borrowings - - - 15.00M 15.00M
Total cash from financing activities 0.41M 234.43M 246.75M 39.61M 0.00800M
Change to operating activities -6.36700M 8.32M -5.48500M 0.26M 0.47M
Net income -113.01200M -192.03600M -91.13000M -27.47400M -21.33700M
Change in cash -101.34500M 60.18M 151.53M 14.71M -21.46800M
Begin period cash flow 233.31M 173.13M 21.60M 6.89M 28.36M
End period cash flow 131.97M 233.31M 173.13M 21.60M 6.89M
Total cash from operating activities -100.13600M -171.38400M -87.02400M -24.32600M -20.94300M
Issuance of capital stock 0.00000M 232.55M 248.19M 24.59M 0.00000M
Depreciation 8.83M 1.58M 0.76M 0.73M 0.65M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - -4.00400M - -
Change to account receivables -0.12500M 0.29M -0.23800M 0.19M -1.99700M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.41M 1.88M -1.43500M -0.57800M 0.00800M
Change to netincome 11.73M 10.25M 4.29M 1.78M 0.68M
Capital expenditures 1.61M 2.87M 8.20M 0.58M 0.53M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -7.68600M 8.82M -0.95100M 0.64M -0.93200M
Stock based compensation 5.37M 9.21M 3.68M 0.96M 0.68M
Other non cash items 6.36M 1.04M 0.61M 0.82M -
Free cash flow -101.75100M -174.25000M -95.22500M -24.90400M -21.47600M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TLIS
Talis Biomedical Corp		 -2.68 61.19% 1.70 - - 7.26 0.22 14.57 0.63
ABT
Abbott Laboratories		 -2.43 2.04% 116.96 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -1.01 0.27% 368.55 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.98 1.06% 91.26 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.22 0.25% 88.29 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.

Talis Biomedical Corp

3400 Bridge Parkway, Redwood City, CA, United States, 94065

Key Executives

Name Title Year Born
Mr. Robert Kelley MBA CEO & Director 1972
Dr. Rustem F. Ismagilov Ph.D. Co-Founder & Director 1974
Mr. J. Roger Moody Jr., M.B.A. Chief Financial Officer 1968
Mr. Liang Li Ph.D. Co-Founder and Director of Technology & Strategy NA
Mr. J. Roger Moody Chief Financial Officer 1968
Ms. Emily Faucette Sr. VP of Corp. Communications & Investor Relations NA
Ms. Jill Green Sr. VP of Legal NA
Mr. Matthew Pepe Sr. Director of Human Resource NA
Ms. Margaret Barrett M.S. Controller NA
Gillian Green Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.